Premium
Temporary iridium‐192 implant in the management of carcinoma of the prostate
Author(s) -
Syed A. M. Nisar,
Puthawala Ajmel,
Austin Peter,
Cherlow Joel,
Perley Jules,
Tansey Larry,
Shanberg Allan,
Sawyer Donald,
Baghdassarian Ruben,
Wachs Barton,
Tomasulo Joseph,
Rao J.,
Syed Rafie
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920515)69:10<2515::aid-cncr2820691022>3.0.co;2-h
Subject(s) - medicine , prostate , prostate carcinoma , prostatectomy , urology , implant , prostate cancer , adenocarcinoma , surgery , cancer
The controversy about the treatment of carcinoma of the prostate has increased in the last decade, with most urologists favoring radical prostatectomy rather than primary irradiation. Several reports of persistent tumors in 50% to 90% of patients after external irradiation and permanent iodine‐125 implantation of the prostate have been disturbing. From July 1977 to December 1985, 200 patients with adenocarcinoma of the prostate were treated by combining bilateral pelvic lymphadenectomy and temporary interstitial iridium‐192 implantation of the prostate, followed by external irradiation. Seventy‐four (36%) patients underwent biopsies of the prostate 4 months to 2 years after completion of the irradiation. Only 12 (16%) patients had persistent tumors. Complications were minimized subsequently by dose modifications.